
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal
Sep 25, 2026 06:52 am UTC| Business Health
Novo Nordisk has agreed to pay up to 1.165 billion ($1.37 billion) to license drug-delivery technology from Swedish biotechnology company Nanexa, potentially paving the way for longer-lasting obesity and diabetes...

FDA Weighs Safety Standards for Psychedelic Therapies
Sep 15, 2026 04:30 am UTC| Governance Health
Doctors, veterans, pharmacists and therapists are calling on the U.S. Food and Drug Administration to establish clear safety and access standards for psychedelic therapies as the Trump administration seeks to accelerate...

Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks
Sep 11, 2026 05:43 am UTC| Business Health
Novartis investors are increasing scrutiny of the Swiss pharmaceutical giants acquisition strategy after recent clinical trial failures raised concerns about its drug pipeline and future growth. The latest setback came...

Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
Sep 08, 2026 16:44 pm UTC| Business Health
Novartis shares plunged more than 10% on Tuesday after the Swiss pharmaceutical giant said its experimental muscle disease drug delpacibart etedesiran, or del-desiran, failed to meet the primary endpoint in a late-stage...

GLP-1 Weight-Loss Drug Use Surges Among U.S. Children
Sep 07, 2026 04:39 am UTC| Health Business
Prescriptions for GLP-1 weight-loss drugs among U.S. children under age 12 have surged more than 300-fold since 2019, as doctors increasingly turn to the medications to treat severe childhood obesity, according to a new...

U.S. Issues Cuba Health Alert as Illnesses Rise
Sep 05, 2026 05:39 am UTC| Politics Governance Health
The U.S. Embassy in Havana issued a health alert for Cuba on Friday after reporting a significant increase in diarrheal and intestinal illnesses linked to deteriorating water and electricity infrastructure across the...

SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Aug 26, 2026 05:21 am UTC| Health Business
SK Biopharmaceuticals has signed a worldwide licensing agreement with Biohaven Bioscience Ireland, securing global rights to the epilepsy drug candidate Opakalim and a portfolio of related Kv7 activator compounds. The...